Molecule
Methamphetamine is an amphetamine anorectic indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 years of age and older. It is available as tablets for oral use. MedsAcross supplies Methamphetamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
1. INDICATIONS AND USAGE Methamphetamine hydrochloride tablets, USP is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 years of age and older. Methamphetamine hydrochloride tablets, USP is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 years of age and older.
Source: US FDA prescribing information
Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in the treatment of ADHD is not known.
Source: US FDA prescribing information
2. DOSAGE & ADMINISTRATION Administer methamphetamine hydrochloride tablets, USP orally once daily or in two divided doses daily. Avoid administration late in the evening due to the risk of insomnia. Recommended starting dosage is 5 mg once or twice a daily. Daily dosage may be increased in 5 mg increments at weekly intervals depending on clinical response. The recommended dosage range is 20 mg to 25 mg daily.
Source: US FDA prescribing information
4. CONTRAINDICATIONS Methamphetamine hydrochloride tablets, USP is contraindicated in patients with: known hypersensitivity to amphetamine, or other components of methamphetamine. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of the risk of hypertensive crisis. Known hypersensitivity to amphetamine, or other components of methamphetamine hydrochloride tablets, USP.
Source: US FDA prescribing information
Boxed warning (abuse, misuse, and addiction methamphetamine): has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including METHAMPHETAMINE, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. 5. WARNINGS AND PRECAUTIONS Risks to Patients with Serious Cardiac Disease: Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease. Increased Blood Pressure and Heart Rate: Monitor blood pressure and pulse. Psychiatric Adverse Reactions: Prior to initiating methamphetamine hydrochloride tablets, USP, screen patients for risk factors for developing a manic episode.
Source: US FDA prescribing information
6. ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Abuse, Misuse, and Addiction Hypersensitivity to amphetamine products or other ingredients of methamphetamine Hypertensive Crisis When Used Concomitantly with Monoamine Oxidase Inhibitors Risks to Patient with Serious Cardiac Disease Increased Blood Pressure and Heart Rate Psychiatric Adverse Reactions Long-Term Suppression of Growth in Pediatric Patients Peripheral Vasculopathy, including Raynaud’s Phenomenon Seizures Serotonin Syndrome Motor and Verbal Tics, and Worsening of Tourette’s Syndrome The following adverse reactions associated with the use of methamphetamine were identified in clinical trials or postmarketing reports.
Source: US FDA prescribing information
7. DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter GI and urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels.
Source: US FDA prescribing information
Store at 20º to 25ºC (68º to 77ºF). Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Methamphetamine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Methamphetamine 5 mg tabletOralGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 31 December 1943 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Methamphetamine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Methamphetamine and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Methamphetamine on 31 December 1943, according to Drugs@FDA.
No listed presentation of Methamphetamine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Methamphetamine is classified under ATC code N06BA03 (Methamphetamine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.